Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD in any field in the pre-index period and 60 days after the index date~* Diagnosis of depression/anxiety in any field and a medication for treating depression/anxiety in the pre-index period and 60 days after the index date~* Index date occurs during identification period~* Patients must be continuously eligible during 1-year pre and 1-year post-index date and be of at least 40 years of age~Exclusion Criteria:~* comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis, and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary tuberculosis, sarcoidosis) during the 1 year pre or post-index periods~* No other maintenance medications other than the index medication on or 60 days after the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COPD patients with comorbid depression/anxiety (Type: None): Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged \>40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.

Based on this trial design, predict the completion outcome and termination type (if applicable).